AtriCure, Inc. (ATRC) Stock

AtriCure, Inc. (ATRC) is a Healthcare stock trading at $47.53 (as of 2026-08-20), with a market capitalization of $2.42B and a trailing P/E of 229.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

AtriCure, Inc. develops and sells surgical treatment systems and related disposable devices for cardiac tissue ablation and procedures involving intercostal nerves. Its product lines include radiofrequency ablation clamps and pens, cryoablation and guided coagulation systems, and implantable or surgical adjunct devices, which it supplies to medical centers in the United States and internationally.

Understand AtriCure, Inc.: how it makes money

AtriCure develops, manufactures, and sells surgical ablation devices and systems for cardiac tissue and intercostal nerves, including single-use disposable radio frequency products, to medical centers, and it makes money from selling these devices and disposables used during procedures.

Because AtriCure sells both procedure tool systems and single-use disposable radio frequency products used in cardiac procedures, its profit engine is tied to clinician and site adoption that drives repeat disposable usage, not just one-time device sales.

Revenue by segment (latest quarter)
US AtriClip$0.0B
US Open Abl Ex Pain$0.0B
US Pain Mgmt$0.0B
International$0.0B

Business quality (Weak): Good visibility into product and geography-related revenue components, but the dataset does not specify the company’s exact official reportable segment names, and several candidate figures look like they may overlap or be rounded relative to the total.

Bull case

  • Single-use disposable product exposure: The company offers single-use disposable radio frequency products (Isolator Synergy Clamps), which can link performance to ongoing procedural use at adopting centers.
  • Multiple clinical product categories: AtriCure sells across appendage management (AtriClip), open ablation products, and pain management products, giving revenue streams beyond one device type.

Bear case

  • Thin operating margin: The latest quarter shows gross margin of 77.4% but operating margin of 0.4%, so operating costs or investment spending can quickly erode gross profit.
  • Adoption and procedure-driven demand: Because sales depend on procedures performed at medical centers using AtriCure devices and related systems, slower clinician adoption or changes in procedure volumes could pressure revenue.
Valuation — source: SEC EDGAR (first-party)
Price$47.53
Market Cap$2.42B
P/E Ratio229.1
EV / EBITDA93.3
Price / Book4.68
Price / Sales4.24
FCF Yield2.2%
DCF Value (model)$10.38
DCF Upside vs Price-78.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$534.53M
Net Margin-2.1%
Revenue Growth (YoY)12.8%
EPS Growth (YoY)-238.5%
FCF Growth (YoY)-2.8%
Financial Health — source: SEC EDGAR
Altman Z-Score9.08 (safe)
Piotroski F-Score7/9 (strong)
Valuation vs Sector & Industry
Stock P/E229.1
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
vs Sector961.0%
vs Industry597.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($193.99M)
Institutional Holders Tracked10
Congressional Trades (recent)4
Company
SectorHealthcare
IndustryMedical Equipment
CEOMichael H. Carrel
Employees1,300
CountryUS
IPO Date2005-08-05

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Pulse Biosciences, Inc. (PLSE)
  • UFP Technologies, Inc. (UFPT)
  • LeMaitre Vascular, Inc. (LMAT)
  • Inspire Medical Systems, Inc. (INSP)
  • KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
  • Tandem Diabetes Care, Inc. (TNDM)
  • Alphatec Holdings, Inc. (ATEC)
  • Integra LifeSciences Holdings Corporation (IART)
ATRC earnings history · ATRC institutional & insider holders · ATRC KPIs & operating metrics · ATRC financials · ATRC investor presentations & press releases · ATRC SEC filings · ATRC peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.